Drugs / super NK cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05987696 | Jul 2023 → Jan 2025 | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | super NK cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05987696 ↗ |
| Modality | Cell therapy | “super NK cell” NCT05987696 ↗ |